The Arrival of JAK Inhibitors: Advancing the Treatment of Immune and Hematologic Disorders

Low dose CP-690,550 (tofacitinib), a pan-JAK inhibitor, accelerates the onset of experimental autoimmune encephalomyelitis by potentiating Th17 differentiation

(2012) Hideyuki Yoshida et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls

(2012) S. Verstovsek et al.   BLOOD

Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease

(2012) Apostolos Kontzias et al.   CURRENT OPINION IN PHARMACOLOGY

JAK2 inhibition for the treatment of hematologic and solid malignancies

(2012) Brian L Harry et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Tofacitinib, a Janus Kinase Inhibitor Demonstrates Efficacy in an IL-15 Transgenic Mouse Model that Recapitulates Pathologic Manifestations of Celiac Disease

(2012) Seiji Yokoyama et al.   JOURNAL OF CLINICAL IMMUNOLOGY

Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition

(2012) Oliver Weigert et al.   JOURNAL OF EXPERIMENTAL MEDICINE

A Patient with Tyrosine Kinase 2 Deficiency without Hyper-IgE Syndrome

(2012) Sara S. Kilic et al.   JOURNAL OF PEDIATRICS

Heterodimeric JAK–STAT activation as a mechanism of persistence to JAK2 inhibitor therapy

(2012) Priya Koppikar et al.   NATURE

JAK inhibition with tofacitinib curbs RANKL-induced joint damage

(2012) Sarah Onuora   Nature Reviews Rheumatology

Placebo-Controlled Trial of Tofacitinib Monotherapy in Rheumatoid Arthritis

(2012) Roy Fleischmann et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis

(2012) Ronald F. van Vollenhoven et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis

(2012) Srdan Verstovsek et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tofacitinib, an Oral Janus Kinase Inhibitor, in Active Ulcerative Colitis

(2012) William J. Sandborn et al.   NEW ENGLAND JOURNAL OF MEDICINE

The JAK inhibitor CP-690,550 (tofacitinib) inhibits TNF-induced chemokine expression in fibroblast-like synoviocytes: autocrine role of type I interferon

(2011) Sanna Rosengren et al.   ANNALS OF THE RHEUMATIC DISEASES

JAK2 rearrangements, including the novel SEC31A-JAK2 fusion, are recurrent in classical Hodgkin lymphoma

(2011) K. Van Roosbroeck et al.   BLOOD

Safety and Efficacy of TG101348, a Selective JAK2 Inhibitor, in Myelofibrosis

(2011) Animesh Pardanani et al.   JOURNAL OF CLINICAL ONCOLOGY

Depletion of Autoreactive Plasma Cells and Treatment of Lupus Nephritis in Mice Using CEP-33779, a Novel, Orally Active, Selective Inhibitor of JAK2

(2011) L. D. Lu et al.   JOURNAL OF IMMUNOLOGY

Cytokine Signaling: Birth of a Pathway

(2011) J. J. O'Shea et al.   JOURNAL OF IMMUNOLOGY

Modulation of Innate and Adaptive Immune Responses by Tofacitinib (CP-690,550)

(2011) Kamran Ghoreschi et al.   JOURNAL OF IMMUNOLOGY

The pseudokinase domain of JAK2 is a dual-specificity protein kinase that negatively regulates cytokine signaling

(2011) Daniela Ungureanu et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis

(2010) Srdan Verstovsek et al.   NEW ENGLAND JOURNAL OF MEDICINE

Phase 1 Dose-Escalation Study of CP-690 550 in Stable Renal Allograft Recipients: Preliminary Findings of Safety, Tolerability, Effects on Lymphocyte Subsets and Pharmacokinetics

(2008) E. van Gurp et al.   AMERICAN JOURNAL OF TRANSPLANTATION

The JAK-3 inhibitor CP-690550 is a potent anti-inflammatory agent in a murine model of pulmonary eosinophilia

(2008) Elizabeth Kudlacz et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Cytokine Signaling Modules in Inflammatory Responses

(2008) John J. O'Shea et al.   IMMUNITY

A quantitative analysis of kinase inhibitor selectivity

(2008) Mazen W Karaman et al.   NATURE BIOTECHNOLOGY